Your browser is no longer supported. Please, upgrade your browser.
Settings
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.80% Shs Outstand109.40M Perf Week-6.31%
Market Cap763.61M Forward P/E- EPS next Y-0.94 Insider Trans-10.68% Shs Float107.03M Perf Month-0.99%
Income-78.90M PEG- EPS next Q-0.24 Inst Own83.00% Short Float8.91% Perf Quarter20.97%
Sales29.10M P/S26.24 EPS this Y-4.10% Inst Trans-1.47% Short Ratio12.63 Perf Half Y36.33%
Book/sh0.47 P/B14.85 EPS next Y-4.40% ROA-47.70% Target Price10.25 Perf Year35.53%
Cash/sh0.74 P/C9.46 EPS next 5Y19.90% ROE-107.80% 52W Range4.12 - 8.13 Perf YTD42.16%
Dividend- P/FCF- EPS past 5Y0.30% ROI-41.50% 52W High-13.78% Beta1.64
Dividend %- Quick Ratio1.20 Sales past 5Y-0.90% Gross Margin96.10% 52W Low70.15% ATR0.37
Employees85 Current Ratio1.20 Sales Q/Q303.20% Oper. Margin- RSI (14)48.29 Volatility4.44% 4.83%
OptionableYes Debt/Eq1.12 EPS Q/Q11.10% Profit Margin- Rel Volume0.25 Prev Close6.98
ShortableYes LT Debt/Eq0.35 EarningsAug 07 BMO Payout- Avg Volume754.82K Price7.01
Recom2.30 SMA20-3.72% SMA505.19% SMA20024.49% Volume53,148 Change0.43%
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Feb-08-16Downgrade Piper Jaffray Overweight → Neutral
Jan-06-16Upgrade Jefferies Hold → Buy
Nov-11-15Downgrade BofA/Merrill Neutral → Underperform
Oct-09-15Downgrade BofA/Merrill Buy → Neutral
Sep-09-15Initiated Jefferies Hold
Sep-17-18 07:00AM  BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever GlobeNewswire
Sep-10-18 12:36PM  Here's Why BioCryst Pharmaceuticals Rose 21.3% in August Motley Fool
Sep-06-18 01:45PM  RTP pharma scores $35M contract to supply CDC American City Business Journals
07:37AM  BioCryst stock surges 6% premarket after winning $35 million CDC contract for flu therapy MarketWatch
07:00AM  CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile GlobeNewswire
Sep-05-18 08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga +5.27%
Sep-04-18 02:38PM  Inside The List: Highest-Paid Public Company CEOs American City Business Journals +6.01%
12:15PM  CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks GlobeNewswire
07:00AM  BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks GlobeNewswire
Aug-29-18 07:00AM  BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference GlobeNewswire
Aug-20-18 01:50PM  Edited Transcript of BCRX earnings conference call or presentation 7-Aug-18 3:00pm GMT Thomson Reuters StreetEvents
Aug-15-18 08:00AM  New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-07-18 03:38PM  BioCryst banks gross proceeds of $57.5M from offering American City Business Journals
07:30AM  BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:05AM  BioCryst: 2Q Earnings Snapshot Associated Press
06:00AM  BioCryst Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-06-18 04:01PM  BioCryst Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock GlobeNewswire
02:18PM  BioCryst gets FDA nod on key drug American City Business Journals
06:00AM  U.S. FDA Grants Fast Track Designation for BioCrysts BCX7353 GlobeNewswire
Aug-02-18 04:13PM  After Idera deal called off, BioCryst looks to raise $50M American City Business Journals +9.96%
02:40PM  Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today Motley Fool
08:54AM  The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter Benzinga
Aug-01-18 09:59PM  BioCryst Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire -6.44%
04:01PM  BioCryst Pharmaceuticals Commences Public Offering of Common Stock GlobeNewswire
Jul-27-18 09:00AM  BioCryst to Announce Second Quarter 2018 Financial Results on August 7 GlobeNewswire
Jul-25-18 06:00PM  BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine GlobeNewswire
Jul-24-18 07:30AM  Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks ACCESSWIRE
Jul-17-18 08:37AM  Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4 Benzinga
Jul-11-18 05:33PM  Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today Motley Fool
02:34PM  Why Idera Pharmaceuticals Is Sinking Today Motley Fool
01:26PM  Spurned at the altar: BioCryst shareholders reject merger with Exton's Idera Pharmaceuticals American City Business Journals
11:56AM  Future of Idera's Cambridge office uncertain after failed merger American City Business Journals
09:23AM  Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie The Wall Street Journal
08:15AM  Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares Benzinga
08:00AM  BioCryst Provides Update on Strategy, Pipeline and Outlook Business Wire
Jul-10-18 06:00PM  No deal: BioCryst shareholders thwart merger with Idera American City Business Journals
05:36PM  [$$] Idera Pharmaceuticals and BioCryst Pharmaceuticals Terminate Merger Plans The Wall Street Journal
04:35PM  BioCryst's stock jumps, Idera drops as proposed merger called off MarketWatch
04:01PM  BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals Business Wire
Jun-25-18 07:15AM  Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks ACCESSWIRE
06:00AM  BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan GlobeNewswire
Jun-20-18 04:20PM  Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. PR Newswire
Jun-13-18 10:28AM  Idera Stock Down, Study on Dermatomyositis Candidate Fails Zacks
07:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-05-18 07:30AM  BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera Business Wire
May-29-18 08:00AM  BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress GlobeNewswire
May-24-18 12:30PM  BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema GlobeNewswire
06:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-17-18 09:00AM  Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks ACCESSWIRE
May-14-18 09:51AM  Edited Transcript of BCRX earnings conference call or presentation 8-May-18 3:00pm GMT Thomson Reuters StreetEvents +9.27%
May-10-18 07:05AM  Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient ACCESSWIRE
May-08-18 10:11AM  Will BioCryst Pharmaceuticals Incs (NASDAQ:BCRX) Earnings Grow In The Years Ahead? Simply Wall St. -9.53%
09:37AM  BioCryst: 1Q Earnings Snapshot Associated Press
06:00AM  BioCryst Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 08:24AM  BioCryst lands European approval for flu treatment American City Business Journals +5.94%
May-01-18 06:00AM  BioCryst Receives European Medicines Agency Approval for ALPIVAB for the Treatment of Influenza GlobeNewswire
Apr-26-18 08:20AM  New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
06:00AM  BioCryst to Announce First Quarter 2018 Financial Results on May 8 GlobeNewswire
Apr-10-18 02:51PM  Vote on proposed merger of biopharm firms pushed back American City Business Journals
07:30AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger Business Wire
Apr-03-18 02:38PM  Why another BioCryst shareholder plans to vote against Idera merger American City Business Journals +5.86%
Apr-02-18 08:13AM  RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals PR Newswire
08:00AM  BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals Business Wire
Mar-29-18 05:21AM  Edited Transcript of BCRX earnings conference call or presentation 27-Feb-18 4:00pm GMT Thomson Reuters StreetEvents
Mar-26-18 04:05PM  Eyenovia Appoints Three Industry Veterans to Board of Directors GlobeNewswire
Mar-23-18 11:00PM  Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals, Inc. (BCRX) GlobeNewswire
Mar-22-18 12:00PM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-20-18 02:58PM  15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies TheStreet.com
Mar-15-18 06:00AM  BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema GlobeNewswire
Mar-09-18 07:50AM  Blog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic Acid ACCESSWIRE
Feb-28-18 06:00AM  BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema GlobeNewswire
Feb-27-18 09:35AM  Does BioCryst Pharmaceuticals Incs (NASDAQ:BCRX) Earnings Growth Make It An Outperformer? Simply Wall St.
09:31AM  BioCryst reports 4Q loss Associated Press
08:30AM  BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
08:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger GlobeNewswire
07:30AM  Analysis: Positioning to Benefit within Healthcare Services Group, Oshkosh, PICO, Chicago Rivet & Machine, Ashland Global, and BioCryst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-26-18 08:45AM  BioCryst, Idera outline specifics on merger value American City Business Journals
08:30AM  Options Traders Expect Huge Moves in BioCryst (BCRX) Stock Zacks
Feb-20-18 06:00AM  BioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27 GlobeNewswire
Feb-19-18 01:00PM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences GlobeNewswire
Feb-16-18 01:20PM  Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. PR Newswire
Feb-05-18 08:39AM  Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock? Zacks
Jan-23-18 09:26AM  BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall Zacks
06:35AM  Cambridge's Idera plans eventual move out of state after merger with BioCryst American City Business Journals
Jan-22-18 04:05PM  BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love Motley Fool
03:53PM  SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of BioCryst Pharmaceuticals, Inc. - BCRX PR Newswire
02:20PM  Durham's BioCryst merging with Idera, moving some ops out of state American City Business Journals
08:41AM  BioCryst and Idera to merge into rare disease company MarketWatch
08:30AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases GlobeNewswire
08:20AM  Todays Research Reports on Trending Tickers: Acorda Therapeutics and BioCryst Pharmaceuticals ACCESSWIRE
Jan-05-18 06:00AM  BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva GlobeNewswire
Jan-03-18 07:00AM  BioCryst to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +6.99%
Jan-02-18 02:02PM  Here's Why BioCryst Pharmaceuticals Gained as Much as 15.7% Today Motley Fool +10.79%
Dec-26-17 11:16AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-20-17 08:10AM  Market Trends Toward New Normal in Ashland Global, BioCryst Pharmaceuticals, PICO, Chicago Rivet & Machine, Mercury General, and IQVIA Holdings Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-11-17 08:20AM  Todays Research Reports on Trending Tickers: BioCryst Pharmaceuticals and 22nd Century Group ACCESSWIRE
07:23AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : December 11, 2017 Capital Cube
Dec-07-17 01:01PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 7, 2017 Capital Cube
Dec-05-17 08:57AM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017 Capital Cube
Dec-04-17 11:16AM  BioCryst Pharmaceuticals, Inc. Value Analysis (NASDAQ:BCRX) : December 4, 2017 Capital Cube
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sheridan William PSenior VP - CMOAug 09Option Exercise1.4262,50088,75085,713Aug 13 10:07 AM
Sheridan William PSenior VP - CMOAug 09Sale7.0362,500439,37523,213Aug 13 10:07 AM
Sheridan William PSenior VP - CMOJun 01Option Exercise2.5842,112108,64963,170Jun 05 03:07 PM
Sheridan William PSenior VP - CMOJun 01Sale6.3042,112265,30621,058Jun 05 03:07 PM
Stonehouse Jon PPresident & CEOMay 17Option Exercise1.4270,427100,006725,519May 21 09:31 AM
Barnes Alane PVP, General Counsel & Corp SecMay 15Option Exercise1.4212,50017,75098,268May 17 09:25 AM
Babu Yarlagadda SSenior VP - Drug DiscoveryMar 06Option Exercise3.2630,00097,800120,618Mar 08 03:48 PM
Stonehouse Jon PPresident & CEOFeb 28Option Exercise3.2656,949185,654698,316Mar 02 02:23 PM
Barnes Alane PVP, General Counsel & Corp SecFeb 28Option Exercise3.266,70921,87185,768Mar 02 02:21 PM
Sheridan William PSenior VP - CMONov 13Sale4.7264,310303,54323,855Nov 15 04:09 PM